Biglycan and related therapeutics and methods of use
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.
1. A method for treating a muscular dystrophy in a subject, comprising administering to the subject a pharmaceutically effective amount of a polypeptide, wherein the polypeptide comprises a sequence at least 90% identical to amino acids 38-365 of SEQ ID NO: 9 and has at least one biological activity of biglycan.
2. The method of claim 1 , wherein the polypeptide comprises at least one repeat motif of 24 amino acids in the Leucine Rich Repeat (LRR) of SEQ ID NO: 9.
3. The method of claim 1 , wherein the polypeptide comprises an amino acid sequence which is identical to amino acids 38-365 of SEQ ID NO: 9.
4. The method of claim 1 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 9.
5. The method of claim 1 , wherein the polypeptide comprises glycosaminoglycan (GAG) side chains.
6. The method of claim 1 , wherein the polypeptide binds to alpha-sarcoglycan and gamma-sarcoglycan.
7. The method of claim 1 , wherein the polypeptide stimulates phosphorylation of alpha-sarcoglycan on a cell membrane.
8. The method of claim 1 , wherein the polypeptide is encoded by a nucleic acid which hybridizes under stringent conditions of 6.0× sodium chloride/sodium citrate (SSC) at about 45° C. to a complementary strand of SEQ ID NO: 8.
9. A method for treating muscle atrophy in a subject, comprising administering to the subject a pharmaceutically effective amount of a polypeptide, wherein the polypeptide comprises a sequence at least 90% identical to amino acids 38-365 of SEQ ID NO: 9 and has at least one biological activity of biglycan.
10. The method of claim 9 , wherein the polypeptide comprises at least one repeat motif of 24 amino acids in the Leucine Rich Repeat (LRR) of SEQ ID NO: 9.
11. The method of claim 9 , wherein the polypeptide comprises an amino acid sequence which is identical to amino acids 38-365 of SEQ ID NO: 9.
12. The method of claim 9 , wherein the polypeptide comprises the amino acid sequence of SEQ ID NO: 9.
13. The method of claim 9 , wherein the polypeptide comprises glycosaminoglycan (GAG) side chains.
14. The method of claim 9 , wherein the polypeptide binds to alpha-sarcoglycan and gamma-sarcoglycan.
15. The method of claim 9 , wherein the polypeptide stimulates phosphorylation of alpha-sarcoglycan on a cell membrane.
16. The method of claim 9 , wherein the polypeptide is encoded by a nucleic acid which hybridizes under stringent conditions of 6.0× sodium chloride/sodium citrate (SSC) at about 45° C. to a complementary strand of SEQ ID NO: 8.